https://scholars.lib.ntu.edu.tw/handle/123456789/542079
標題: | Perioperative changes in TGF-β1 levels predict the oncological outcome of cryoablation-receiving patients with localized prostate cancer | 作者: | Wang A.S.-S. CHUNG-HSIN CHEN Chou Y.-T. YEONG-SHIAU PU |
公開日期: | 2016 | 出版社: | Academic Press Inc. | 卷: | 73 | 期: | 1 | 起(迄)頁: | 63-68 | 來源出版物: | Cryobiology | 摘要: | Purpose To evaluate the cytokine transforming growth factor beta 1 (TGF-β1) as a predictor of oncological outcomes in patients after cryoablation. Materials and methods Perioperative blood samples from prostate cancer (PC) patients who underwent total gland cryoablation between October 2011 and March 2013 were collected prospectively. Plasma TGF-β1 levels were quantified using magnetic bead immunoassay. The perioperative change in TGF-β1 was defined as the change in TGF-β1 from before surgery to 1–2 months after surgery. Biochemical recurrence (BCR) was defined according to the Phoenix criteria. The Mann–Whitney U, Kruskal–Wallis rank sum, and Chi-square test were used to compare the clinical characteristics of the subsets. The Cox proportional hazard model was applied for the comparison of recurrence risk among the groups. Results A total of 75 PC patients were included. During a median follow-up period of 12 months (range: 2.5–47 months), 11 patients had BCR, and 64 patients did not. Significantly greater changes in the perioperative TGF-β1 levels (median: 470.3 vs. 78.9 pg/ml) were observed in patients with than without BCR (p < 0.05). According to the changes in TGF-β1 levels, the patients were further divided into 4 groups, which were determined in the quartile categories of perioperative TGF-β1 levels. Group 4 (?430) predicted the worst BCR outcome. Conclusions Perioperative plasma TGF-β1 levels were associated with BCR after prostate cryoablation for localized PC. Increase in postoperative plasma TGF-β1 may be a novel predictor for poor oncological outcomes and prompt a more aggressive follow-up or earlier salvage treatment. ? 2016 Elsevier Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84971634537&doi=10.1016%2fj.cryobiol.2016.05.011&partnerID=40&md5=f387df4f49d0ff886182780e9b099ebc https://scholars.lib.ntu.edu.tw/handle/123456789/542079 |
ISSN: | 0011-2240 | DOI: | 10.1016/j.cryobiol.2016.05.011 | SDG/關鍵字: | prostate specific antigen; transforming growth factor beta1; transforming growth factor beta1; tumor marker; adult; aged; Article; biochemical recurrence; biochemical recurrence free survival; cancer prognosis; controlled study; cryoablation; follow up; Gleason score; human; human tissue; major clinical study; male; predictive value; priority journal; prostate cancer; protein blood level; biosynthesis; blood; cryosurgery; immunoassay; middle aged; pathology; procedures; proportional hazards model; Prostatic Neoplasms; tumor recurrence; Aged; Biomarkers, Tumor; Cryosurgery; Humans; Immunoassay; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Prostatic Neoplasms; Transforming Growth Factor beta1 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。